Compare Stocks: BTAI, EQ, SPRB, and CUE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTAI BioXcel Therapeutics	$1.19 +5.3%	$1.04	$0.74 ▼ $6.85	$34.89M	0.31	531,627 shs	2.03 million shs
CUE Cue Biopharma	$34.20 +10.0%	$29.50	$4.97 ▼ $45.50	$130.55M	2.47	195,652 shs	157,074 shs
EQ Equillium	$2.36 +17.4%	$2.65	$0.76 ▼ $3.54	$127.08M	1.82	511,463 shs	537,963 shs
SPRB Spruce Biosciences	$52.64 +5.8%	$48.37	$7.00 ▼ $240.00	$143.04M	3.23	47,462 shs	42,267 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTAI BioXcel Therapeutics	+6.60%	+36.11%	+9.71%	-0.88%	-79.82%
CUE Cue Biopharma	+2.17%	+15.07%	-0.64%	+35.07%	-95.74%
EQ Equillium	-7.80%	-5.19%	-27.17%	-7.80%	+116.13%
SPRB Spruce Biosciences	+5.74%	+7.22%	+7.36%	-7.46%	+453.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTAI BioXcel Therapeutics	$1.19 +5.3%	$1.04	$0.74 ▼ $6.85	$34.89M	0.31	531,627 shs	2.03 million shs
CUE Cue Biopharma	$34.20 +10.0%	$29.50	$4.97 ▼ $45.50	$130.55M	2.47	195,652 shs	157,074 shs
EQ Equillium	$2.36 +17.4%	$2.65	$0.76 ▼ $3.54	$127.08M	1.82	511,463 shs	537,963 shs
SPRB Spruce Biosciences	$52.64 +5.8%	$48.37	$7.00 ▼ $240.00	$143.04M	3.23	47,462 shs	42,267 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTAI BioXcel Therapeutics	+6.60%	+36.11%	+9.71%	-0.88%	-79.82%
CUE Cue Biopharma	+2.17%	+15.07%	-0.64%	+35.07%	-95.74%
EQ Equillium	-7.80%	-5.19%	-27.17%	-7.80%	+116.13%
SPRB Spruce Biosciences	+5.74%	+7.22%	+7.36%	-7.46%	+453.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTAI BioXcel Therapeutics	2.25	Hold	$11.00	824.37% Upside
CUE Cue Biopharma	1.00	Sell	N/A	N/A
EQ Equillium	2.91	Moderate Buy	$7.57	220.82% Upside
SPRB Spruce Biosciences	2.75	Moderate Buy	$161.88	207.51% Upside

Current Analyst Ratings Breakdown

Latest BTAI, EQ, SPRB, and CUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	SPRB Spruce Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Overweight
8/13/2026	SPRB Spruce Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/13/2026	SPRB Spruce Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$150.00 ➝ $144.00
8/12/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	EQ Equillium	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/21/2026	EQ Equillium	Clear Str Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	BTAI BioXcel Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	EQ Equillium	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
7/13/2026	EQ Equillium	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/13/2026	SPRB Spruce Biosciences	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$160.00
6/24/2026	EQ Equillium	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTAI BioXcel Therapeutics	$640K	57.42	N/A	N/A	($4.37) per share	-0.27
CUE Cue Biopharma	$27.47M	5.23	N/A	N/A	$10.08 per share	3.39
EQ Equillium	$41.10M	3.63	N/A	N/A	$0.47 per share	5.02
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	$39.72 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTAI BioXcel Therapeutics	-$69.90M	-$5.75	N/A	N/A	N/A	-11,078.53%	N/A	-201.53%	N/A
CUE Cue Biopharma	-$26.60M	-$5.58	N/A	N/A	N/A	-59.65%	-98.30%	-53.69%	8/14/2026 (Estimated)
EQ Equillium	-$22.40M	-$0.32	N/A	N/A	N/A	N/A	-61.43%	-53.72%	N/A
SPRB Spruce Biosciences	-$38.97M	-$39.78	N/A	N/A	N/A	N/A	-186.62%	-123.74%	N/A

Latest BTAI, EQ, SPRB, and CUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CUE Cue Biopharma	-$1.69	-$24.14	-$22.45	-$24.14	$3.00 million	$7.88 million
8/13/2026	Q2 2026	BTAI BioXcel Therapeutics	-$0.44	-$0.49	-$0.05	-$0.49	$0.49 million	$0.18 million
8/13/2026	Q2 2026	EQ Equillium	-$0.0540	-$0.04	+$0.0140	-$0.04	N/A	N/A
8/12/2026	Q2 2026	SPRB Spruce Biosciences	-$5.79	-$6.68	-$0.89	-$6.68	N/A	N/A
5/15/2026	Q1 2026	BTAI BioXcel Therapeutics	-$0.5325	-$0.54	-$0.0075	-$0.54	$0.38 million	$0.21 million
5/14/2026	Q1 2026	CUE Cue Biopharma	-$3.30	-$1.08	+$2.22	-$1.08	$2.50 million	$5.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTAI BioXcel Therapeutics	N/A	0.62	0.61
CUE Cue Biopharma	N/A	3.57	3.57
EQ Equillium	N/A	18.62	18.62
SPRB Spruce Biosciences	0.16	4.67	4.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTAI BioXcel Therapeutics	30.68%
CUE Cue Biopharma	35.04%
EQ Equillium	27.05%
SPRB Spruce Biosciences	91.71%

Insider Ownership

Company	Insider Ownership
BTAI BioXcel Therapeutics	3.70%
CUE Cue Biopharma	14.56%
EQ Equillium	17.84%
SPRB Spruce Biosciences	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTAI BioXcel Therapeutics	90	30.88 million	29.74 million	No Data
CUE Cue Biopharma	60	4.20 million	3.59 million	Optionable
EQ Equillium	40	63.23 million	51.95 million	Not Optionable
SPRB Spruce Biosciences	20	2.75 million	2.63 million	Optionable

BTAI, EQ, SPRB, and CUE Headlines

Recent News About These Companies

Spruce Biosciences (NASDAQ:SPRB) Given New $144.00 Price Target at Citizens Jmp

August 13 at 10:11 AM | marketbeat.com

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 12 at 11:54 PM | aol.comA

Spruce Biosciences (NASDAQ:SPRB) Issues Quarterly Earnings Results, Misses Estimates By $0.89 EPS

August 12 at 1:10 PM | marketbeat.com

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

August 12 at 8:52 AM | finance.yahoo.com

Spruce Biosciences (SPRB) to Announce Quarterly Earnings on Thursday

August 6, 2026 | marketbeat.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 4, 2026 | americanbankingnews.com

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

August 3, 2026 | finance.yahoo.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 30, 2026 | marketbeat.com

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

July 27, 2026 | finance.yahoo.com

Spruce Biosciences Names Adrian Quartel Chief Medical Officer

July 27, 2026 | tipranks.com

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

July 8, 2026 | finance.yahoo.com

Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy

July 8, 2026 | seekingalpha.com

Spruce Biosciences Joins the Russell 3000® Index

June 29, 2026 | finance.yahoo.com

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

June 15, 2026 | finance.yahoo.com

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

June 8, 2026 | businesswire.com

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

May 28, 2026 | businesswire.com

Spruce Biosciences to Participate in Upcoming Conferences in June

May 27, 2026 | businesswire.com

Spruce Biosciences Stockholders Approve Directors and Annual Say-on-Pay

May 26, 2026 | tipranks.com

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 13, 2026 | businesswire.com

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President ...

May 4, 2026 | bakersfield.comB

Craig-Hallum initiates coverage of Spruce Biosciences (SPRB) with buy recommendation

April 28, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BTAI, EQ, SPRB, and CUE Company Descriptions

BioXcel Therapeutics NASDAQ:BTAI

$1.19 +0.06 (+5.31%)

Closing price 04:00 PM Eastern

Extended Trading

$1.20 +0.01 (+0.42%)

As of 07:54 PM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Cue Biopharma NASDAQ:CUE

$34.20 +3.12 (+10.04%)

Closing price 04:00 PM Eastern

Extended Trading

$33.00 -1.20 (-3.51%)

As of 07:52 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Equillium NASDAQ:EQ

$2.36 +0.35 (+17.41%)

Closing price 04:00 PM Eastern

Extended Trading

$2.32 -0.04 (-1.91%)

As of 07:34 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Spruce Biosciences NASDAQ:SPRB

$52.64 +2.87 (+5.77%)

Closing price 04:00 PM Eastern

Extended Trading

$52.70 +0.06 (+0.11%)

As of 07:34 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BTAI, EQ, SPRB, and CUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BTAI, EQ, SPRB, and CUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BTAI, EQ, SPRB, and CUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BTAI, EQ, SPRB, and CUE Company Descriptions

BioXcel Therapeutics NASDAQ:BTAI

Cue Biopharma NASDAQ:CUE

Equillium NASDAQ:EQ

Spruce Biosciences NASDAQ:SPRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BTAI, EQ, SPRB, and CUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BTAI, EQ, SPRB, and CUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BTAI, EQ, SPRB, and CUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BTAI, EQ, SPRB, and CUE Company Descriptions

BioXcel Therapeutics NASDAQ:BTAI

Cue Biopharma NASDAQ:CUE

Equillium NASDAQ:EQ

Spruce Biosciences NASDAQ:SPRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools